The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three to four final candidates, according

The Supreme Court restored mail ordering of mifepristone reversing a federal appeals court’s stay. The decision Monday came after makers of the pill asked for

A new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there’s a

A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.